Schäfer Ann-Kathrin C, Pieper Dennis, Dihazi Hassan, Dihazi Gry H, Lüders Stephan, Koziolek Michael J, Wallbach Manuel
Department of Nephrology and Rheumatology, University Medical Center Göttingen, 37075 Göttingen, Germany.
Center for Biostructural Imaging of Neurodegeneration (BIN), University Medical Center Göttingen, 37075 Göttingen, Germany.
J Clin Med. 2023 Jan 29;12(3):1034. doi: 10.3390/jcm12031034.
Patients with resistant hypertension (HTN) demonstrate an increased risk of chronic kidney disease and progression to end-stage renal disease; however, the individual course of progression is hard to predict. Assessing the stress-induced, urinary glycoprotein Dickkopf-3 (uDKK3) may indicate ongoing renal damage and consecutive estimated glomerular filtration rate (eGFR) decline. The present study aimed to determine the association between uDKK3 levels and further eGFR changes in patients with resistant HTN. In total, 31 patients with resistant HTN were included. Blood pressure and renal function were measured at baseline and up to 24 months after (at months 12 and 24). uDKK3 levels were determined exclusively from the first available spot urine sample at baseline or up to a period of 6 months after, using a commercial ELISA kit. Distinctions between different patient groups were analyzed using the unpaired t-test or Mann-Whitney test. Correlation analysis was performed using Spearman's correlation. The median uDKK3 level was 303 (interquartile range (IQR) 150-865) pg/mg creatinine. Patients were divided into those with high and low eGFR loss (≥3 vs. <3 mL/min/1.73 m²/year). Patients with high eGFR loss showed a significantly higher median baseline uDKK3 level (646 (IQR 249-2555) (n = 13) vs. 180 (IQR 123-365) pg/mg creatinine (n = 18), = 0.0412 (Mann-Whitney U)). Alternatively, patients could be classified into those with high and low uDKK3 levels (≥400 vs. <400 pg/mg creatinine). Patients with high uDKK3 levels showed significantly higher eGFR loss (-6.4 ± 4.7 (n = 11) vs. 0.0 ± 7.6 mL/min/1.73 m/year (n = 20), = 0.0172 (2-sided, independent t-test)). Within the entire cohort, there was a significant correlation between the uDKK3 levels and change in eGFR at the latest follow-up (Spearman's r = -0.3714, = 0.0397). In patients with resistant HTN, high levels of uDKK3 are associated with higher eGFR loss up to 24 months later.
顽固性高血压(HTN)患者患慢性肾病及进展至终末期肾病的风险增加;然而,个体的进展过程很难预测。评估应激诱导的尿糖蛋白Dickkopf-3(uDKK3)可能提示正在发生的肾损伤以及随后估计肾小球滤过率(eGFR)的下降。本研究旨在确定uDKK3水平与顽固性HTN患者eGFR进一步变化之间的关联。总共纳入了31例顽固性HTN患者。在基线时以及之后长达24个月(第12个月和第24个月)测量血压和肾功能。使用商用ELISA试剂盒,仅从基线时或之后长达6个月内首次获得的随机尿样中测定uDKK3水平。使用非配对t检验或Mann-Whitney检验分析不同患者组之间的差异。使用Spearman相关性进行相关分析。uDKK3水平的中位数为303(四分位间距(IQR)150 - 865)pg/mg肌酐。患者被分为eGFR损失高和低的两组(≥3 vs. <3 mL/min/1.73 m²/年)。eGFR损失高的患者基线uDKK3水平中位数显著更高(646(IQR 249 - 2555)(n = 13) vs. 180(IQR 123 - 365)pg/mg肌酐(n = 18),P = 0.0412(Mann-Whitney U))。或者,患者可分为uDKK3水平高和低的两组(≥